When Massachusetts health system Partners Healthcare announced new industry interaction recommendations for doctors on Friday, it was just the latest piece of erosion in the changing landscape of the healthcare-pharma relationship. The recommendations came days after a similar announcement from Johns Hopkins and one month after Partner's home state set statewide rules limiting pharma gifts to physicians.
Although these new policies may seem like an onslaught on the pharmaceutical industry, Partners says they put their policy in place to make the symbiotic relationship stronger.
“I think there are many important aspects of the relationships between academia and industries that we need to preserve and protect," says Peter Slavin, MD, the president of Massachusetts General Hospital, who is leading the implementation efforts across Partners. “It's in our interest and in the public's interest that we focus our relationship with these issues and try to eliminated some of the noise that cause some people to call into question the value of the [pharma-healthcare] relationship. I think it will make the relationships stronger and by working together it will help the people we're trying to serve."
Extravagant dinners and ghostwritten articles are unnecessary distractions, while drug research and trials are paramount, he says.
Similarly, the Johns Hopkins policies were written to prevent any aspects of marketing from getting involved with drug research and physician interaction.
"This policy is designed to try to put the emphasis on relationship with industry—where many people believe it should be," says Julie Gottlieb, assistant dean for policy coordination at Johns Hopkins University School of Medicine. "That [focus] is on science and medicine exchanges that will advance patient care—and not on marketing."
Ideally, these conflict-of-interest policies will create strong ties that better facilitate the exchange of ideas between healthcare organizations and pharma researchers, she says.
“Ultimately none of us want to see a situation were our medical care is compromised because of a financial relationship between pharmaceutical company and that doctor," says Retta M. Riordan, president of Riordan Consulting in Mountainside, NJ and former compliance officer for Organon BioSciences. “Similarly we don't want to see the results of a research doctor being swayed as a result of the relationship. It would be horrendous from a research standpoint, a patient standpoint, and a company standpoint."
But the most recent regulations, like those implemented by Partners and Johns Hopkins, have gone too far, Riordan says.
“What has happened is these conflict-of-interest policies have been morphing into much more," she says. “They basically have been looking at every contact with pharma as being bad. I think these extremely restrictive policies don't benefit anyone, least of all the patient."
Slavin admits that the new Partners policy has caused dissent in the pharmaceutical industry and even within the organization itself, but they are prepared to deal with the consequences.
“We really feel very strongly that relationship between Partners and industry is critical to us achieving our mission," he says. “By restricting certain things they will liberate us to focus more energy on the important things between our organization and industry."
The next step for Partners will be to turn broad recommendations into specific policies ready for implementation.
“I hope by working together we can develop new agents that can help the lives of our patients and the public in general," he says. “I hope in five years from now this is less of a concern to public policy members, the media, and the public at large."
Johns Hopkins is less optimistic about the future of the healthcare-pharma relationship, and it will adjust its policies as the environment changes, Gottlieb says. "If industry decides to find new and different ways to market their products that also undermine independent decision making by physicians and researchers, then we have to address those," she says. "I hope that's not the case."
Riordan, too, is thinking about the future.
“We may see some more of these restrictive policies coming on board," she says. “What we don't want to see is a total restriction on interactions between physician and drug companies. I think people have stepped over a little too far in one direction, but I'm hoping that the pendulum will swing back."
Moses Cone Health System in Greensboro, NC, has sent letters offering free credit monitoring to 14,380 patients after a laptop computer containing confidential information was stolen from a vendor in Canton, GA. The health system said the information on the computer was not encrypted but was password-protected and contained a software program that requires training and expertise to use. Moses Cone said the health system does not know of any instance in which the information has been disclosed or misused or if the laptop was taken for that purpose.
Starting this year, New Jersey tax filers are being asked if they have uninsured children, and those who do are being directly sent a so-called "express" state child insurance application. The applications are for the state's FamilyCare program, which covers New Jersey children who fall in the gap between Medicaid and private insurance. The program provides free or low-cost medical exams, shots, hospitalization, lab tests, X-rays, prescription drugs, and dental and mental health services. It serves nearly 132,000 children and 128,000 adults.
New Jersey seniors are readmitted to hospitals more often than those in most other states, often because of what experts say are preventable breakdowns in care. Now Virtua Health plans to launch an ambitious effort to tackle this problem by better educating its departing patients and reconnecting them to family doctors. The system hopes to ease the often treacherous transition period when medication errors often occur and follow-up care can be missed.
Culver City, CA-based Brotman Medical Center, with the help of the Jewish Home for the Aging, emerged from bankruptcy protection in a way that may result in a new senior living facility. The 420-bed hospital said it returned to profitability after securing $29 million in financing, including $23 million in loans from the Jewish home. In exchange, the Jewish home received an option to buy land next to and owned by the hospital for the possible construction of a senior living facility.
After 60 days of dealmaking, compromise, and defeat, the fate of West Virginia's remaining healthcare legislation is now in the hands of Gov. Joe Manchin. Without committing himself to definite actions, Manchin held out cautious praise for a proposal to create a new office to oversee healthcare in the state. One proposal would establish pilot projects for "medical home" healthcare models in which a physician or clinic coordinates all aspects of a patient's care.